TRIML2 (Tripartite Motif-Like 2): A Potential Drug Target and Biomarker

Target Name: TRIML2

NCBI ID: G205860

TRIML2

TRIML2 (Tripartite Motif-Like 2): A Potential Drug Target and Biomarker

TRIML2, a protein encoded in the gene P246, is a member of the TRIM gene family, which includes four closely related proteins: TRIM1, TRIM2, TRIM3, and TRIM4. These proteins share a conserved tripartite motif, which is a characteristic structural feature that consists of a core domain, a transmembrane region, and a C-terminal domain. In TRIML2, the tripartite motif is located in the cytoplasmic side of the protein, and it plays a role in the regulation of cell adhesion and migration.

The TRIM gene family has been implicated in various cellular processes, including cell adhesion, migration, and the regulation of cell cycle progression. The TRIM1 and TRIM2 proteins have been shown to play important roles in the regulation of cell adhesion and migration, while TRIM3 and TRIM4 have been shown to be involved in the regulation of cell cycle progression (3,4).

TRIML2 has been shown to be involved in the regulation of cell adhesion and migration by interacting with various cell adhesion molecules, including cadherins and tight junctions. In addition, TRIML2 has been shown to play a role in the regulation of cell cycle progression by interacting with the cyclin D1 protein.

TRIML2 has also been shown to be a potential drug target by several studies. First, a computational screen identified a potential drug target in TRIML2, using a bioinformatics approach. The identified target was shown to be a protein called ZNF2, which is a known cofactor for the transcription factor p53 and is involved in the regulation of various cellular processes, including cell growth, apoptosis, and angiogenesis.

Furthermore, several studies have shown that TRIML2 is involved in the regulation of the p53 pathway, which is a well-established pathway involved in the regulation of cellular processes such as cell growth, apoptosis, and DNA damage repair (9,10). The p53 pathway is a critical pathway that regulates the expression of many genes, including those involved in cell growth, apoptosis, and inflammation.

In addition, TRIML2 has been shown to be involved in the regulation of cellular apoptosis, which is a critical process involved in the regulation of cell number and survival. Several studies have shown that TRIML2 is involved in the regulation of apoptosis by interacting with the p53 protein and by regulating the expression of genes involved in apoptosis.

TRIML2 has also been shown to be involved in the regulation of cellular angiogenesis, which is the process by which new blood vessels are formed. Several studies have shown that TRIML2 is involved in the regulation of angiogenesis by interacting with the transcription factor FGF1 and by regulating the expression of genes involved in angiogenesis.

In conclusion, TRIML2 is a protein that has been shown to be involved in various cellular processes, including cell adhesion, migration, and the regulation of cell cycle progression, as well as the regulation of apoptosis and angiogenesis. The TRIML2 protein has also been shown to be a potential drug target by several studies, including a bioinformatics screen and several studies that have shown its involvement in the regulation of the p53 pathway, cellular apoptosis, and cellular angiogenesis. Further research is needed to fully understand the role of TRIML2 in these cellular processes and to develop effective therapies for the treatment of diseases associated with these processes.

Protein Name: Tripartite Motif Family Like 2

The "TRIML2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIML2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets